News Breaks |
|
|
| January 16, 2013 |
| 06:42 EDT |  | IRWD | Ironwood downgraded to Sell from Neutral at UBS
UBS downgraded Ironwood citing reduced Linzess expectations and rich valuation. Price target lowered to $11.50 from $14. |
|
|
News For IRWD From The Last 14 Days Check below for free stories on IRWD the last two weeks. |
|
|
| May 22, 2013 |
| 06:47 EDT |  | IRWD | Ironwood likely to raise money again in early 2014, says Cantor
Cantor believes Ironwood's 10.5M share offering provides the company with adequate cash for another three-to-four quarters of operations. However, Cantor thinks Ironwood will need to raise money again in early 2014 and reiterates a Sell rating on the stock with a $9 price target. |
|
| May 21, 2013 |
| 18:30 EDT |  | IRWD | Ironwood 10.5M share Secondary priced at $13.00
JPMorgan, BofA/Merrill and Morgan Stanley acted as joint book running managers for the offering. |
|
| May 20, 2013 |
| 16:05 EDT | | IRWD | Ironwood files to sell 10.5M shares of common stock
J.P. Morgan and BofA Merrill Lynch are acting as joint bookrunning managers and as representatives of the underwriters for the offering. Morgan Stanley is acting as bookrunning manager for the offering. |
|
| 07:11 EDT | | IRWD | Ironwood Linzess may not be suitable for some patients, says Cantor
After analyzing clinical data, Cantor believes that doctors will stop prescribing Ironwood's Linzess to patients who are not getting relief from constipation from the drug initially, while other patients will stop using the drug after two to three months. After attending two events connected with the launch of the drug, the firm thinks interest in it is disappointing, and it reiterates a Sell rating on the stock. |
|
| May 17, 2013 |
| 10:36 EDT |  | IRWD | Leerink's major/specialty pharma analyst holds analyst/Industry conference call
 Subscribe for More Information |
|
| May 15, 2013 |
| 11:37 EDT |  | IRWD | High option volume stocks: CONN IRWD JASO LYV CSC
|
|
|
|
|
|
